Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
CSL, GSK and Sanofi
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)
Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.
GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.
BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was disclosed by the Administration for Strategic Preparedness and Response,
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
It would more than double the country's supply of shots targeting bird flu, raising the country's total supply of ready-to-use doses to 10 million within the first quarter of 2025. GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu,
1d
Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
14h
GSK falls Friday, underperforms market
GSK PLC GSK shares inched down 0.07% to £14.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.02% to 8,280.63. Supported ...
Malay Mail on MSN
1d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
2d
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
11d
GSK’s ex-vaccines chief says its jab for a flu-like virus is too expensive
GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too ...
9d
GSK CEO Is Trying to Move Past Zantac ‘Overhang’ on Shares
GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...
LancasterOnline
8d
GSK expansion project in East Donegal Township could get a tax break
East Donegal Township is considering a tax break that would benefit an expansion of the GSK vaccine packaging facility in ...
12d
Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback